The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by He, Y.
Right arrow Articles by Pinter, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by He, Y.
Right arrow Articles by Pinter, A.
The Journal of Immunology, 2002, 169: 595-605.
Copyright © 2002 by The American Association of Immunologists

Efficient Isolation of Novel Human Monoclonal Antibodies with Neutralizing Activity Against HIV-1 from Transgenic Mice Expressing Human Ig Loci1

Yuxian He*, William J. Honnen*, Chavdar P. Krachmarov*, Michael Burkhart*, Samuel C. Kayman*, Jose Corvalan{dagger} and Abraham Pinter2,*

* Laboratory of Retroviral Biology, Public Health Research Institute, Newark, NJ 07103; and {dagger} Abgenix, Inc., Fremont, CA 94555

Despite considerable interest in the isolation of mAbs with potent neutralization activity against primary HIV-1 isolates, both for identifying useful targets for vaccine development and for the development of therapeutically useful reagents against HIV-1 infection, a relatively limited number of such reagents have been isolated to date. Human mAbs (hu-mAbs) are preferable to rodent mAbs for treatment of humans, but isolation of hu-mAbs from HIV-infected subjects by standard methods of EBV transformation of B cells or phage display of Ig libraries is inefficient and limited by the inability to control or define the original immunogen. An alternative approach for the isolation of hu-mAbs has been provided by the development of transgenic mice that produce fully hu-mAbs. In this report, we show that immunizing the XenoMouse G2 strain with native recombinant gp120 derived from HIVSF162 resulted in robust humoral Ab responses against gp120 and allowed the efficient isolation of hybridomas producing specific hu-mAbs directed against multiple regions and epitopes of gp120. hu-mAbs possessing strong neutralizing activity against the autologous HIVSF162 strain were obtained. The epitopes recognized were located in three previously described neutralization domains, the V2-, V3- and CD4-binding domains, and in a novel neutralization domain, the highly variable C-terminal region of the V1 loop. This is the first report of neutralizing mAbs directed at targets in the V1 region. Furthermore, the V2 and V3 epitopes recognized by neutralizing hu-mAbs were distinct from those of previously described human and rodent mAbs and included an epitope requiring a full length V3 loop peptide for effective presentation. These results further our understanding of neutralization targets for primary, R5 HIV-1 viruses and demonstrate the utility of the XenoMouse system for identifying new and interesting epitopes on HIV-1.




This article has been cited by other articles:


Home page
 J. Virol.Home page
J. M. Binley, E. A. Lybarger, E. T. Crooks, M. S. Seaman, E. Gray, K. L. Davis, J. M. Decker, D. Wycuff, L. Harris, N. Hawkins, et al.
Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C
J. Virol., December 1, 2008; 82(23): 11651 - 11668.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. K. Dhillon, H. Donners, R. Pantophlet, W. E. Johnson, J. M. Decker, G. M. Shaw, F.-H. Lee, D. D. Richman, R. W. Doms, G. Vanham, et al.
Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors
J. Virol., June 15, 2007; 81(12): 6548 - 6562.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
W. J. Honnen, C. Krachmarov, S. C. Kayman, M. K. Gorny, S. Zolla-Pazner, and A. Pinter
Type-Specific Epitopes Targeted by Monoclonal Antibodies with Exceptionally Potent Neutralizing Activities for Selected Strains of Human Immunodeficiency Virus Type 1 Map to a Common Region of the V2 Domain of gp120 and Differ Only at Single Positions from the Clade B Consensus Sequence
J. Virol., February 1, 2007; 81(3): 1424 - 1432.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
N. C. Sheppard, S. L. Davies, S. A. Jeffs, S. M. Vieira, and Q. J. Sattentau
Production and Characterization of High-Affinity Human Monoclonal Antibodies to Human Immunodeficiency Virus Type 1 Envelope Glycoproteins in a Mouse Model Expressing Human Immunoglobulins
Clin. Vaccine Immunol., February 1, 2007; 14(2): 157 - 167.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
N. R. Derby, Z. Kraft, E. Kan, E. T. Crooks, S. W. Barnett, I. K. Srivastava, J. M. Binley, and L. Stamatatos
Antibody Responses Elicited in Macaques Immunized with Human Immunodeficiency Virus Type 1 (HIV-1) SF162-Derived gp140 Envelope Immunogens: Comparison with Those Elicited during Homologous Simian/Human Immunodeficiency Virus SHIVSF162P4 and Heterologous HIV-1 Infection.
J. Virol., September 1, 2006; 80(17): 8745 - 8762.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
Y. Li, K. Svehla, N. L. Mathy, G. Voss, J. R. Mascola, and R. Wyatt
Characterization of Antibody Responses Elicited by Human Immunodeficiency Virus Type 1 Primary Isolate Trimeric and Monomeric Envelope Glycoproteins in Selected Adjuvants
J. Virol., February 1, 2006; 80(3): 1414 - 1426.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
S. Selvarajah, B. Puffer, R. Pantophlet, M. Law, R. W. Doms, and D. R. Burton
Comparing Antigenicity and Immunogenicity of Engineered gp120
J. Virol., October 1, 2005; 79(19): 12148 - 12163.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. Pinter, W. J. Honnen, P. D'Agostino, M. K. Gorny, S. Zolla-Pazner, and S. C. Kayman
The C108g Epitope in the V2 Domain of gp120 Functions as a Potent Neutralization Target When Introduced into Envelope Proteins Derived from Human Immunodeficiency Virus Type 1 Primary Isolates
J. Virol., June 1, 2005; 79(11): 6909 - 6917.
[Abstract] [Full Text] [PDF]

Home page
 Protein Eng Des SelHome page
R. Pantophlet, I.A. Wilson, and D.R. Burton
Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12
Protein Eng. Des. Sel., October 1, 2004; 17(10): 749 - 758.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Paul, S. Karle, S. Planque, H. Taguchi, M. Salas, Y. Nishiyama, B. Handy, R. Hunter, A. Edmundson, and C. Hanson
Naturally Occurring Proteolytic Antibodies: SELECTIVE IMMUNOGLOBULIN M-CATALYZED HYDROLYSIS OF HIV gp120
J. Biol. Chem., September 17, 2004; 279(38): 39611 - 39619.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. Pinter, W. J. Honnen, Y. He, M. K. Gorny, S. Zolla-Pazner, and S. C. Kayman
The V1/V2 Domain of gp120 Is a Global Regulator of the Sensitivity of Primary Human Immunodeficiency Virus Type 1 Isolates to Neutralization by Antibodies Commonly Induced upon Infection
J. Virol., May 15, 2004; 78(10): 5205 - 5215.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. D. Burkhart, S. C. Kayman, Y. He, and A. Pinter
Distinct Mechanisms of Neutralization by Monoclonal Antibodies Specific for Sites in the N-Terminal or C-Terminal Domain of Murine Leukemia Virus SU
J. Virol., April 1, 2003; 77(7): 3993 - 4003.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2002 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2002 by The American Association of Immunologists, Inc. All rights reserved.